Objective.-To search for differences in prevalence of a CACNA1E variant between migraine without aura, various phenotypes of migraine with aura, and healthy controls.
INTRODUCTION
Migraine is a frequent disorder, characterized by headache attacks that may be preceded or accompanied by neurological symptoms in about 30% of patients. 1 These include visual, sensory, and motor disturbances and are globally defined as "migraine auras." In the International Classification of Headache Disorders-3 beta, 2 migraine with aura is subdivided into nine subtypes, according to the presence or not of headache and the clinical features of the aura, in particular the presence of motor or basilartype symptoms and the familial occurrence of the disease. Migraine is known to run in families and great efforts have been made in the last two decades to identify its genetic determinants. At present, the only monogenic forms of migraine with functionally relevant mutations in a single gene are familial hemiplegic migraine (FHM), [3] [4] [5] sporadic hemiplegic migraine (SHM), [6] [7] [8] and migraine with brainstem aura (BM). 9, 10 These are phenotypically similar subtypes of migraine with aura, differentiated by familial occurrence or not, the presence of a unilateral motor deficit, or of symptoms attributable to brain stem dysfunction. 2 Familial hemiplegic migraine type 1 (FHM1) (ICHD-3beta 1.2.3.1.1), as well as some cases of SHM (1.2.3.2) [6] [7] [8] and BM (1.2.2), 9 are caused by mutations in the CACNA1A gene (Chr 19p13), coding for the alpha 1A (Ca v 2.1) pore-forming subunit of P/Q voltage-dependent Ca 21 channels.
Mutations in the ATP1A2 gene (Chr 1q23), coding for the main subunit of the Na/K ATPase pump have been found in FHM2, 4 SHM2, 6, 8 and BM. 10 FHM has also been associated with mutations on the SCN1A gene (Chr 2q24), coding for the a1 subunit of the neuronal Na V 1.1 sodium channel (FHM3). 5 However, some FHM families do not bear mutations on these genes, so that other FHM genes are to be expected. The FHM mutations are not found in the common forms of migraine with or without aura. Linkage analyses and particularly genome-wide association studies have identified multiple susceptibility loci as single nucleotide polymorphisms (SNPs). 11, 12 A locus on chromosome 1 (1q31) was initially found to be associated with FHM 13 and later with the common migraine types with and without aura. 14 17, 18 No significant difference was found between patients and controls, but in the first study 17 only one CACNA1E SNP marker was studied compared to four in the second, 18 and all dbSNP markers had a rather high minor allele frequency ranging from 0.27 to 0.47. We decided therefore to explore more extensively the CACNA1E gene by using different markers and by studying various clinical phenotypes of migraine with aura. Our aim was to search for differences in prevalence of CACNA1E variants between migraine phenotypes and healthy controls.
METHODS
Patients' Enrollment.-Patients and healthy controls were recruited at the Headache Centre of the IRCCS Neuromed (Pozzilli, IS, Italy) and the Headache Research Unit of the University of Liè ge (Belgium) between 2001 and 2006. All migraineurs were outpatients followed in both headache centers; healthy controls were recruited among the medical and administrative staff, as well as students and research fellows attending both hospitals. The study was conducted in accordance with the Declaration of Helsinki and approved by the local ethics committees. Blood sampling (10 mL) from cubital veins, and genetic testing were performed with the written informed consent of the subjects. NonCaucasian subjects were excluded in order to reduce genetic variability. None of the patients and healthy volunteers had a familial relationship with other participants in the study. The blood samples were collected by the Laboratory of Neuropharmacology of the IRCCS Neuromed, where the DNA extraction and gene screening was performed.
We recruited 98 migraine patients (71 females and 27 males) and 102 healthy controls (72 females and 30 males). When the first genetic analyses were performed, patients were diagnosed according to ICHD-II criteria 19 that did not allow a distinction between FHM subtypes. As soon as ICHD3beta 2 was published with the subdivision of FHM into three genetically distinct subtypes, we rescreened all FHM and SHM patients for mutations in CACNA1A (FHM1), ATP1A2 (FHM2), and SCN1A (FHM3) genes known up to 2013. Consequently, using ICHD3beta criteria, 2 patients were diagnosed as suffer- The latter three groups of patients were globally called migraine with complex neurological aura (MAplus).
Mutation Screening.-Genetic testing was performed by direct sequencing of blood genomic DNA. In a first step, three probands (2 BM and 1 FHM) with a strong family history were chosen for a total screening of exons in the CACNA1A, ATP1A2, and SCN1A genes. UTRs were not taken into consideration. They underwent a total screening of the CACNA1E gene by sequencing on an ABI PRISM 3700 capillary sequencer (Applied Biosystems, Foster City, CA, USA). We identified a dbSNP rs35737760 (Asp859Glu in exon 20) in one proband. The dbSNP rs35737760 has genomic coordinates chr1:181732663 in Human Genome version GRCh38/hg38; it is located on exon 20 of NM_000721.3 transcript and corresponds to variant Asp859Glu. Following the identification of the Asp859Glu substitution, we extended the study to migraineurs and controls by restriction fragment length polymorphism (RFLP) analysis. The Asp859Glu polymorphism was analyzed by PCR-RFLP analysis, using the restriction endonuclease FoKI (New England Biolabs). The PCR reactions were performed using the following primers:
Forward: CTGAGGAAGCACATGCAGAT (Sense) Hairpin Blast.
Reverse: ATCCTGGGCTCTCTCTTCTT (AntiSense) Hairpin Blast.
An amplicon of 588 bp was obtained at standard PCR conditions (T m 5 628C).
Statistical Analyses.-No power analysis was made before starting this study, which was aimed to recruit as many migraine with aura patients as possible. Due to the low prevalence of patients with complex auras and the involvement of only two tertiary headache centers, we were not able to predict how many patients we would be able to enroll for analyses. The frequencies of (Asp859Glu -rs35737760) variations were calculated from the observed variation counts. The association of frequencies to the different migraine subtypes was investigated by inserting dichotomized data (wild type and mutated) for the analyzed migraine groups (controls, MO, MTA, MAPlus) in 2 3 2 contingency tables for patients and controls. The association between the selected genetic variation and the migraine type was analyzed with the 2-tailed Fisher's exact test using RBioconductor package. The significance level was set to 0.05. The computed P values were corrected for multiple comparisons using both the classical Bonferroni procedure to control the Family Wise Error Rate (FWER), and the Benjamini and Hochberg procedure to control for False Discovery Rate (FDR). P values corrected with both methods are shown in Table 1 .
RESULTS
We identified a single nucleotide polymorphism (variation Asp859Glu -rs35737760) in exon 20 of the CACNA1E gene, not previously recognized to link to migraine. This variation was found in 12.7% of control subjects and in 20.4% of the total group of migraine patients, a difference that did not reach statistical significance (see Table 1 ).
However, the Asp859Glu variant was significantly more represented (42.1%) in FHM, SHM, and BM patients -called here MAplus subgroupthan in control subjects, with an odds ratio (OR) of 4.98 (95% CI: 1.69-14.67, uncorrected P 5 .005, Bonferroni P 5 .030, 2-tailed Fisher's exact test). The prevalence of the polymorphism was larger in the MAplus subgroup than in MTA patients (OR 5 5.76: 95% CI: 1.3-24.88), which was statistically significant (uncorrected P 5 .006, Bonferroni P 5 .034, 2-tailed Fisher's exact test).
In migraine without aura (MO), but not in migraine with typical aura (MTA), there was a slight numerical, but non-significant, overrepresentation of the Asp859Glu variant compared to controls (25.0%; OR 5 2.28, 95% CI: 0.82-3.76, uncorrected P 5 .200, Bonferroni P 5 1.000, 2-tailed Fisher's exact test).
DISCUSSION
We report on a single nucleotide polymorphism (SNP) in exon 20 of the CACNA1E gene (Asp859Glu -rs35737760) not studied in migraine up to now. This SNP was overrepresented in the subtype of migraine with aura characterized by complex neurological symptoms such as familial or sporadic hemiplegic and brainstem aura migraine not associated with mutations in the known FHM genes. The association was statistically significant, but we are aware that our sample size was small and that replication studies are necessary in an independent, and if possible larger, cohort, to confirm our results. Compared to healthy controls, it tended to be numerically more frequent in migraine without aura patients, but surprisingly had a low prevalence in migraine with typical aura. patients with a post-concussion syndrome, the CACNA1E SNP was found to be associated with increased balance deficits, which are also common in FHM patients, 26 arguing in favor of its functional significance. We will limit this discussion to four neural phenomena in which a modulation by Ca v 2.3 channels might be relevant for migraine pathophysiology: (1) cortical spreading depression (CSD); (2) neuromuscular transmission and cerebellar function; (3) thalamocortical rhythms; (4) trigeminal nociception. First, CSD is likely the culprit for the migraine aura. FHM1 CACNA1A mutations facilitate CSD and glutamate release in knock in mice. 27 After blockade of P/Q-type Ca21 channels CSD cannot be induced in wild-type mouse cortical slices. By contrast, blockade of R-type Ca21 channels has only a minor inhibitory effect on CSD. 28 Consequently, if the Asp859Glu -rs35737760 SNP in patients with complex neurological auras changes the functional properties of R-type Ca21 channels, this change is not likely to have a major effect on CSD. However, while P/Q Ca21 channels are seminal in action potential-induced exocytosis, R-type Ca21 channels play a greater role in spontaneous glutamate release. 29 It remains to be determined whether R-type Ca21 channels may favor spreading depression in subcortical areas 30 that are relevant for aura symptoms in BM. 31 Lamotrigine is known to inhibit CSD in rats after chronic treatment 32 and to be effective in preventing attacks of MTA, 33, 34 FHM, SHM, and BM. 35, 36 Interestingly, lamotrigine is able to inhibit Ca v 2.3 (R-type) calcium currents. 37 Whether this contributes to its therapeutic effect in migraine with aura remains to be proven. Along the same line, topiramate, another inhibitor of CSD during long-term treatment in rats 38 with preventive action in both migraine with and without aura, was shown to depress R-type Ca21 channels in hippocampal neurons. 39 Second, we have described subtle abnormalities in transmission at the neuromuscular junction (NMJ) in migraine patients that were confirmed by others. [40] [41] [42] [43] [44] These abnormalities are restricted to migraine with aura patients and most pronounced in patients with prolonged 42 and complex neurological auras, 40, 41, 43, 44 precisely in the present study the subgroup of patients with the highest prevalence of the Asp859Glu polymorphism. The carbonic anhydrase inhibitor acetazolamide that is able to normalize the impairment of neuromuscular transmission 45 The insert II in the I-II loop that characterizes this isoform is located in exon 20, where the Asp859Glu variant is located. Moreover, zolmitriptan, one of the 5HT1B/D agonists effective in acute migraine treatment, was reported to inhibit R-type Ca21 channels in dissociated rat trigeminal neurons. 61 
CONCLUSIONS
Up until now the CACNA1E gene that encodes the main subunit of R-type (Ca v 2.3) voltagegated calcium channels has received little attention in migraine. Given the distribution and functional roles of Ca v 2.3 channels, mutations in the CACNA1E gene could in theory be responsible for some aspects of migraine pathophysiology. We report here that a single nucleotide polymorphism in this gene leading to the substitution of aspartate by glutamate in exon 20 is overrepresented in patients suffering from migraine with complex neurological auras. The functional consequences of this substitution are not yet known and probably minor, but this polymorphism could interplay with other genetic abnormalities to modify ion channel function, as previously shown for specific CACNA1A polymorphisms in migraine. 62 While awaiting the results of functional studies, available data on the functional neuroanatomy of Ca v 2.3 channels set the scene for a possible role in spreading depression, neuromuscular transmission and cerebellar function, thalamocortical loops, and trigeminal nociception, all of which can be impaired in migraine and its subtypes. Needless to say, further studies are necessary to prove these hypotheses. 
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